Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
We investigated the treatment of experimental autoimmune encephalomyelitis (EAE) in mice with Niaspan, an agent used to elevate high-density lipoprotein (HDL). EAE mice were treated with Niaspan starting on the immunization or clinical onset day. Neurological functional recovery was significantly increased in the Niaspan treated mice (100 mg/kgbw) compared to the controls. Inflammatory infiltrates were significantly reduced in the Niaspan treatment group compared to the EAE controls. HDL level, intact myelin area, newly formed oligodendrocytes, regenerating axons, gene and protein levels of sonic hedgehog (Shh)/Gli1 were significantly increased in the Niaspan treated mice compared to EAE controls. These data indicate that Niaspan treatment improved functional recovery after EAE, possibly, via reducing inflammatory infiltrates and demyelination areas, and stimulating oligodendrogenesis and axonal regeneration. Niaspan-mediated activation of Shh/Gli1 pathway may promote functional recovery post-EAE.
Zhang
Jing
J
Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA.
Chen
Jieli
J
Li
Yi
Y
Cui
Xu
X
Zheng
Xuguang
X
Roberts
Cynthia
C
Lu
Mei
M
Elias
Stanton B
SB
Chopp
Michael
M
D000818:Animals; D002461:Cell Line, Transformed; D049109:Cell Proliferation / Q000187:drug effects; D008076:Cholesterol, HDL / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D053823:Hedgehog Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D018991:Myelin Proteolipid Protein / Q000009:adverse effects; D009416:Nerve Regeneration / Q000187:drug effects; D009525:Niacin / Q000627:therapeutic use*; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism; D020127:Recovery of Function / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D014803:Vitamin B Complex / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D053823:Hedgehog Proteins; D018991:Myelin Proteolipid Protein; C465570:Shh protein, mouse; D014803:Vitamin B Complex; D009525:Niacin
Development. 1999 Jun;126(11):2419-29
10226001
J Neuropathol Exp Neurol. 1993 Jan;52(1):55-63
8381162
Ann N Y Acad Sci. 1988;540:712-4
2462842
Lab Invest. 1991 Mar;64(3):358-70
2002654
Mol Cell Neurosci. 2007 Nov;36(3):355-68
17826177
Am J Cardiol. 1998 Dec 17;82(12A):29U-34U;  discussion 39U-41U
9915660
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):695-7
12754330
J Biol Chem. 2007 Nov 2;282(44):32462-70
17804404
J Neurotrauma. 1992 Mar;9 Suppl 1:S93-103
1588636
Curr Med Res Opin. 2006 Feb;22(2):417-25
16466614
J Neurosci Res. 2008 May 15;86(7):1501-10
18214988
Mult Scler. 2003 Aug;9(4):362-71
12926841
J Neurosci Res. 2001 Nov 15;66(4):691-7
11746389
Int J Biochem Cell Biol. 1998 Mar;30(3):407-15
9611781
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1724-31
12969988
Glia. 2002 Oct;40(1):55-64
12237843
Neuron. 1997 Jul;19(1):197-203
9247275
Nat Rev Neurosci. 2002 Apr;3(4):291-301
11967559
J Neurosci. 2004 May 5;24(18):4432-43
15128857
Pathol Biol (Paris). 2000 Feb;48(1):80-6
10729915
Nature. 2005 Oct 6;437(7060):894-7
16208373
Nat Rev Cancer. 2002 May;2(5):361-72
12044012
Development. 2001 Feb;128(4):527-40
11171336
Glia. 2005 Oct;52(1):1-15
15892129
Development. 2007 Jan;134(2):285-93
17166924
Glia. 2004 Apr 15;46(2):207-17
15042587
Mol Cell Neurosci. 2002 Mar;19(3):320-32
11906206
Lab Invest. 1981 Dec;45(6):534-46
7321526
Atherosclerosis. 1978 Dec;31(4):465-71
215176
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13466-71
15353595
Nature. 1983 Jun 2-8;303(5916):390-6
6304520
Am J Cardiol. 1998 Dec 17;82(12A):74U-81U;  discussion 85U-86U
9915666
Glia. 1996 May;17(1):39-51
8723841
J Neurosci Res. 1995 Apr 1;40(5):680-93
7541477
Metabolism. 1998 Sep;47(9):1097-104
9751239
J Neurochem. 2007 Apr;101(2):298-312
17402967
Neurosci Lett. 1992 Feb 3;135(2):219-23
1625798
Brain. 2006 Aug;129(Pt 8):1953-71
16632554
J Neuropathol Exp Neurol. 2005 May;64(5):404-11
15892298
Am J Cardiol. 1998 Sep 15;82(6):737-43
9761083
EMBO J. 2004 Nov 10;23(22):4495-505
15496983
Circ Res. 2004 Oct 15;95(8):764-72
15486323
Int J Clin Pract. 2004 Jul;58(7):706-13
15311728
J Nutr Sci Vitaminol (Tokyo). 1982 Oct;28(5):491-500
7161647
Purinergic Signal. 2008 Mar;4(1):61-71
18368534
J Biol Chem. 2000 Jun 30;275(26):19883-90
10867025
Glia. 1998 Feb;22(2):161-70
9537836
Nature. 1986 Feb 6-12;319(6053):499-502
3945333
Brain. 1994 Jun;117 ( Pt 3):563-78
8032866
J Clin Invest. 1989 Mar;83(3):1015-31
2493483
Expert Opin Pharmacother. 2004 Jun;5(6):1385-98
15163282
Neth J Med. 2004 Jul-Aug;62(7):229-34
15554597
Nat Med. 1999 Feb;5(2):170-5
9930864
J Neurosci Res. 2001 Jan 15;63(2):124-35
11169622
Ann Neurol. 2000 Jun;47(6):707-17
10852536
Dev Neurosci. 2001;23(6):452-63
11872946
J Neurosci. 2000 Sep 1;20(17):6404-12
10964946
Dev Neurosci. 2007;29(6):413-26
17119318
Am J Pathol. 1979 Jun;95(3):683-96
453329
J Neurosci Res. 2006 Mar;83(4):606-18
16435391
Am J Cardiol. 1998 Dec 17;82(12A):35U-38U;  discussion 39U-41U
9915661
J Neurochem. 2001 Jan;76(2):498-508
11208913
Dev Neurosci. 1995;17(3):160-70
8549427
Methods. 2001 Dec;25(4):402-8
11846609
J Neurosci Res. 1999 Sep 1;57(5):633-42
10462687
J Neurochem. 1993 Feb;60(2):577-87
7678286
Ann Neurol. 2007 Jul;62(1):49-58
17557352
Brain. 2002 Oct;125(Pt 10):2202-12
12244078
Lab Invest. 1989 Nov;61(5):489-503
2811298
Genes Dev. 2001 Dec 1;15(23):3059-87
11731473
J Cell Biol. 1989 Nov;109(5):2405-16
2553746
Brain Res. 2005 Feb 9;1034(1-2):34-9
15713257
Trends Neurosci. 2002 Feb;25(2):89-96
11814561
Exp Neurol. 2005 Sep;195(1):16-26
15904921
Nature. 1984 Mar 15-21;308(5956):274-5
6700730